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The needs and benefits of sharing health data to advance scientific research and improve clinical 
benefits have been well documented in recent years, specifically in the field of rare diseases where 
knowledge and expertise are limited and patient populations are geographically dispersed. 
Understanding what patients want and need from rare disease research and data sharing is important 
to ensure their participation and engagement in the process, and to ensure that these wishes and 
needs are embedded within research design. EURORDIS-Rare Diseases Europe regularly surveys the 
rare disease community to identify its perspectives and needs on a number of issues in order to 
represent rare disease patients and be their voice within European and International initiatives and 
policy developments.    
Here, we present key findings from a large quantitative survey conducted with patients with rare 
diseases and family members as part of a continuous evidence-based advocacy process developed at 
EURORDIS. The aim of this survey was to explore patient and family perspectives on data sharing and 
data protection in research and healthcare settings and develop relevant recommendations to support 
shaping of future data sharing initiatives in rare disease research.  
This survey, translated into 23 languages, was carried out via the Rare Barometer Programme and was 
designed to be accessible to a diverse population with a wide range of education backgrounds. It was 
widely disseminated via patient organisations worldwide to ensure that a wide range of voices and 
experiences were represented.  
 
Main findings 
Rare disease patients, regardless of the severity of their disease and their socio-demographic profile, 
are clearly supportive of data sharing to foster research and improve healthcare. However, rare disease 
patieŶts͛ ǁilliŶgŶess to share their data does come with specific requirements in order to respect their 
privacy, choices and needs for information regarding the use of their data. 
Conclusions 
To ensure sustainability and success of international data sharing initiatives in health and research for 
rare diseases, appropriate legislations need to be implemented and multi-stakeholder efforts need to 
be pursued to foster cultural and technological changes enabling the systematic integration of 





rare diseases; quantitative survey, data sharing, data protection, patient engagement, 
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INTRODUCTION 
We live in an information age with exponential increases in biomedical information available to 
support scientific advances and inform health care decisions. These developments are propelled by 
͚oŵiĐ͛ ƌeseaƌĐh - genomics, transcriptomics, metabolomics, proteomics, etc. – made possible through 
the increased technical capacity to produce and store large datasets, amidst decreasing technical costs 
;‘ehŵ ϮϬϭϳ; ThoŵpsoŶ et al. ϮϬϭϰͿ. This ŵoǀe toǁaƌds ͚ďig data͛ has sigŶifiĐaŶt iŵpliĐatioŶs: the 
capacity to analyse collective biomedical information raises significant and challenging questions on 
how to exploit its potential while protecting the interests of individual contributors and stakeholders 
(Council of the European Union, 2017). Within this current landscape, there is an imperative to make 
effective and timely use of the data to ensure translation towards improvement in clinical outcomes. 
It is now broadly recognised that this is only possible through collective endeavours: the true potential 
of biomedical data can only be realised through its capacity to be combined and shared. Sharing data 
- rather than data operated in isolation from others - is now recognised as one of the most important 
ways to ensure benefits for all, including patients, families, scientists, funders, health care providers 
and future users of the healthcare systems. The basic principal behind data sharing is that the scientific 
community should, wherever possible, pool their data to gain the maximum benefit from it; this would 
be, for example, combining two or more datasets from researchers working in the same area, to make 
one large dataset, which then becomes more statistically significant.  
High pƌofile iŶitiatiǀes, foĐusiŶg oŶ ďoth ͚healthǇ͛ aŶd disease-linked populations attest to the value of 
embedding data sharing in their design (Haeusermann et al. 2017), and this is particularly evident for 
projects exploiting the potential of new genetic technologies which are propelling the big data 
revolution. The Human Genome Project, completed in 2003, which succeeded in mapping the human 
genome, was only possible through widespread international collaboration. A more recent example is 
the UK 100,000 Genomes Project, which was launched by Genomics England with the aim to sequence 
100,000 genomes of NHS patients with the intention to support scientific and clinical advances, and to 
create an NHS genomic medical service.  
Shared informational data enables a much deeper and broader understanding of the nature of disease 
and patient populations than was previously possible. It can provide a greater evidence base for 
improving clinical outcomes, informing clinical trials, and supporting the development of drugs and 
devices. It can also improve and speed up the diagnostic process, improve its accuracy and 
consequently reduce health costs. Overall, there are clear financial benefits in terms of reducing 
duplication and speeding up the process from bench to bedside. For example, Figueiredo (2017) argues 
that data sharing is a way of returning the investment that society has made in science through public 
funded research or charity. As a consequence, sharing data is imperative in the context of rare disease 
research. As most rare diseases have a genetic component, clinical benefits are now possible through 
the developments of genomic technologies, yet sharing rare disease data is further complicated by the 
nature of rare disease. There are more than 6,000 rare diseases which represents great biomedical and 
clinical variability. Low prevalence rates, few if any centres of expertise and wide geographical spread 
can make it difficult to identify adequate numbers of patients at a local level to inform a valid evidence 
base. Thompson et al. (2014) highlight an example of a trial for juvenile dermatomyositis, where 103 
clinical centres were involved in recruiting 130 patients. Data sharing within, and 
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groups can produce knowledge more efficiently by minimising the potential for duplicated studies, but 
also reducing the burden of research on small yet willing patient communities (El Emam et al. 2015).  
The role of patient communities has been well documented in raising awareness of little known 
medical conditions and campaigning for access to research funding and healthcare resources (Allsop, 
Jones and Baggot, 2004). Patients with a rare disease are increasingly willing to engage with research 
as it often offers the only hope of accessing a diagnosis or benefitting from a treatment or a cure. Yet 
the willingness of patients and their families to support the scientific research agenda and engage with 
biomedical research and data sharing can leave them vulnerable. One of the problems with rare 
diseases has been that the hope and promises associated with developments in technologies have 
often been slow to translate into clinical outcomes, and that while there might be scientific merit, 
patient communities have often not experienced any benefit. At the extreme end, some have felt 
exploited in the race for scientific gain (see for example the problems within the research partnership 
focusing on Canavan Disease, as documented in Novas 2006).  
This article contributes to the debate by identifying key issues about data sharing, enabling support for 
research while ensuring that participants are protected. Understanding what patients want from rare 
disease research and data sharing is important to ensure their participation and engagement in the 
process, and also to ensure that consideration of their needs are embedded within research design.  
Although the benefits of sharing data are clear, there are numerous technical and regulatory 
boundaries which make sharing difficult and for many researchers, clinicians and institutions, still not 
standard practice. Data sharing requires a level of compatibility which can be difficult to implement in 
practice. With preferred systems and protocols, practices which dictate what kinds of data can be 
collected and what can be done with it, these multiple systems, owned or managed by different 
institutions, different countries and different regulatory rules can be incompatible. However, aside 
from technical issues, there is a different kind of barrier noted by Contreras and Reichman (2015) and 
otheƌs, that ŵaŶǇ iŶstitutioŶs do Ŷot haǀe a ͚Đultuƌe͛ of shaƌiŶg data ǁhiĐh ǁould ŵake iŶtƌoduĐiŶg 
new data sharing initiatives more difficult. Many researchers work closely within geographic, 
iŶstitutioŶal oƌ disĐipliŶaƌǇ ďouŶdaƌies. IŶ the ĐoŶteǆt of ͚silo ŵeŶtalities͛, shaƌiŶg data is ƌeplete ǁith 
ĐoŶĐeƌŶ aďout ƌiskiŶg the peƌsoŶal aŶd pƌofessioŶal ďeŶefits gaiŶed thƌough ͚oǁŶeƌship͛ of data. The 
American College of Medical Genetics and Genomics position statement (ACMG 2017) identified a 
͚pƌe-Đoŵpetitiǀe spaĐe͛ ǁheƌe the ďeŶefits of shaƌiŶg Đould ďe ǁidelǇ distƌiďuted. Although the 
College recognises that sharing of data is vital for ensuring genetic health care and securing improved 
ĐliŶiĐal outĐoŵes, it suggests that this ǁill ƌeƋuiƌe a ͚paƌadigŵ shift͛ iŶ ƌeseaƌĐh aŶd pƌaĐtiĐe. 
Conflicting needs of contributors have been addressed by introducing an embargo period which 
protects the interests of scientific lead partners while ensuring that data can remain open and available 
to others (Contreras, 2015).  
The challenges faced by investigators in relation to data sharing are compounded by the hurdles 
inherent in rare disease research, including iŶǀestigatoƌs͛ laĐk of kŶoǁledge aŶd uŶdeƌstaŶdiŶg of the 
context of rare disease, difficulties in accessing funding and developing new treatments (Griggs et al., 
2009). Although Griggs et al. (2009) are right to some extent in noting that rare disease patients are 
often willing research participants, there are many barriers to participation which need consideration. 
Key issues associated with data sharing, such as consent, anonymity and trust are important not only 
because they offer participants a level of protection in the research, but also because the way these 
issues are managed has sigŶifiĐaŶt iŵpliĐatioŶs foƌ patieŶts͛ peƌspeĐtiǀes oŶ ƌeseaƌĐh aŶd theiƌ 
willingness to engage. 
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Thompson et al. (2014) highlight how the risks of collecting, storing and manipulating large data sets 
are informational rather than physical. With much publicised cases of data hacking, data security is of 
course paramount, but there are more fundamental issues to consider: the production and availability 
of digital biomedical data has created concerns around privacy and consent, as well as ownership and 
control.  
Understanding issues of consent within any biomedical field is often a priority for researchers. Yet 
informed consent can be rendered meaningless because of the complexity of the research and its 
purposes. This is particularly so in relation to the genomic revolution, where there is a long history of 
acknowledging complex issues around consent, and where there is often an acknowledged lag 
between research and treatment - the multifarious purposes for collecting and storing biomedical 
information compare with medical research with more tangible and local clinical applications. Consent 
around genetic medicine for example is complicated by the importance of collecting family data 
(Takashima et al. 2018) and gaining consent from children (Burke and Clarke 2016, McCormack et al. 
2016). It also has the potential for incidental findings (Hallowell et al. 2018) and where future 
developments in technology and diagnostic capacity might mean re-contacting patients with new 
information (Sirchia et al. 2018).  
Different models of consent which have been identified specifically in relation to rare disease patient 
communities include broad, dynamic and opt-in. Gainotti et al. (2016) for example explored issues 
around patient consent for those involved in international collaborative rare disease research, and 
highlight, as others have done, the pressing need for advanced planning. They make a distinction 
between data that has already been collected (and which is bound to already received consent and its 
limitations) and new research which can be collected under new guidelines. They conclude that for 
ŶeǁlǇ ĐolleĐted data, ͞ďƌoadlǇ desĐƌiďed research purposes with ongoing updates for participants is 
the ďest ĐuƌƌeŶt solutioŶ͟ (Gainotti et al. 2016 p1253). They see this as allowing the flexibility to adapt 
to new circumstances and technologies but also one that protects participants and ensures 
transparency.  
McCormack et al. (2016) found that patients valued being asked to re-consent when a research 
purpose changed. They stated that ĐoŶseŶt is ͞a soĐial agƌeeŵeŶt͟, aŶd deĐisioŶs aďout ƌeseaƌĐh aƌe 
not automatically conferred to the research team or ethics panel. Current practice within many 
countries and institutions has often been based on the premise that data re-use is less ethically 
contentious when it can be anonymised (El Emam et al. 2015). Anonymity is a complex issue in the 
case of biomedical information, made more difficult for rare disease patients because the risks of 
identification are higher due to the much smaller populations and made even more complex because 
of the frequent requirement to collect family data. The information which is important for 
characterising the biological nature of a particular rare disease are precisely the kinds of information 
which can identify the patient. With such small populations, identifying the name of the disease and 
the country of residence might be sufficient to identify an individual patient. Although discrimination 
on the basis of genetic information is regulated in the US (with the adoption of the Genetic Information 
Nondiscrimination Act of 2008) as well as across many EU countries, other countries have yet to initiate 
discussions about the risks associated with genetic knowledge. Offering rare disease patients the 
opportunity to have feedback, while protecting their identity through anonymity remains a challenge. 
‘aƌe disease patieŶts͛ peƌspeĐtives are needed to contribute to the debate on the management, 
sharing and protection of data, in order to reconcile tensions within the research process with what 
matters most to patients. McCormack et al. (2016) found that patients are aware of and concerned 
about questions of data security and misuse. They also recognised their vulnerability associated with 
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having a rare disease and that knowledge generated through genomic developments and data sharing 
could lead to their discrimination. 
The dominant picture which emerges from current research is that patients are willing to contribute 
their data but continue to have concerns about data sharing. The European Commission survey 
programme (Special Eurobarometer, 2018, 2015) for example identified that a sense of control is 
important for citizens involved in research, yet currently they often do not feel in control of what 
happens to their data. Trust is a key issue for patients involved in rare disease research, and it could 
be argued that this becomes even more evident in data sharing, with the onus on researchers, 
institutions and collaborations to recognise this as a responsibility. Focusing on those with a rare 
disease, MĐCoƌŵaĐk et al. ;ϮϬϭϲͿ ƌepoƌt that ͞paƌtiĐipaŶts haǀe high leǀels of tƌust iŶ puďliĐ 
iŶstitutioŶs͟ aŶd theǇ eǆpeĐt that iŶstitutioŶs ǁill, aŶd should, ƌeĐogŶise theiƌ ƌight foƌ theiƌ pƌiǀaĐǇ, 
and their data to be protected and used effectively. Darquay et al. (2016) found similar results, that 
patients (in their case members of a European leukodystrophies database) supported data sharing in 
order to generate greater knowledge and clinical outcomes. Patients wished for continued information 
and transparency, they demonstrated trust in the researchers and ethics committees to protect their 
interests, but most importantly, to enable research to progress.  
Supporting continuous and open communication with participants might be onerous for researchers 
and collaborators, but it recognises the crucial role that participants play within the research process. 
Including patients at the design stage of projects can ensure the feasibility of research protocols, and 
can help ensure its success (Merkel et al. 2016). More importantly, understanding the perspectives of 
patients and engaging them in the process is key for promoting and maintaining trust within the 
patient-research relationship, and highlights the importance of solidarity, reciprocity and co-
production (Minion et al. 2018). There are also issues about recruitment and retention. Researchers 
continue to stress the importance of informed consent, even though opting out could be problematic 
for research given such low numbers and the high value of participation. Gainotti et al. (2016) for 
example underlines the crucial importance of supporting patients in expressing their informed consent 
and allowing the time, care and resources that this requires. A major concern linked to rare disease 
research, given the significance of participation is that, as the technology develops, or new purposes 
or collaborations are found, re-gaining consent risks losing participants at each stage. Parallels can be 
drawn with the experience of recruitment and retention of minority research participants, where 
distrust is a significant barrier, and where community involvement and ongoing communication can 
support engagement. 
The present survey and suggested recommendations are specifically relevant today in view of wider 
changes in regulation and attitudes towards data. The implementation of the General Data Protection 
Regulation (GDPR) engenders a greater awareness of the value of data, issues of ownership and privacy 
and highlights potential risks to participants. Haeusermann et al. (2018) explored the reasons why 
individuals shared their own personal health data online. They found that participants who were 
openly sharing their own data continued to have concerns about privacy, and that the motivation for 
sharing despite this risk was that it could lead to new developments. But they identified that choosing 
to make public their private data was based on a knowledge of, and compromise around, the risks and 
benefits. Thus a contradiction has emerged, between the widespread use of social media and a greater 
freedom in sharing data, amidst rising concerns about privacy (Rainie 2018). 
The International Rare Diseases Research Consortium (IRDiRC) was established in 2011 in an effort to 
support global collaboration on research for rare diseases. RD-Connect was one of the first projects to 
be funded under the IRDiRC initiative (see Thompson et al. 2014). RD-Connect is a large EU-funded 
project aiming at developing an integrated platform connecting databases, registries, biobanks and 
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clinical bioinformatics for rare disease research (Thompson 2014; McCormack et al. 2016). EURORDIS-
Rare disease Europe is actively involved in IRDiRC activities as well as in RD-Connect, including the 
coordination of a Patient Advisory Council (PAC) to inform all project partners of issues important to 
patients and guaranteeing a patient-centric approach throughout the various activities (Lochmüller et 
al., 2018). This survey forms part of a broader mixed methods approach to exploring perspective on 
data sharing and protection that was initiated through RD-Connect. The findings of related qualitative 
projects conducted through RD-Connect have previously been published (McCormack et al. 2016). 
Indeed the present quantitative survey represents an important contribution in providing a more 
detailed picture of the experiences and opinions of those living with a rare disease.  
The present study is part of a continuous evidence-based advocacy process developed at EURORDIS. 
Evidence-based advocacy is generally described as involving the use of research to influence policy 
(Court et al. 2006, Kaare et al. 2007).  Evidence refers to a result or output of a research process that 
can include any process of investigation such as data collection, analysis and codification that can be 
used to inform policies. Evidence-based initiatives seek social transformation by advocating for the 
rights of the most vulnerable (Kaare et al. 2007). As a European umbrella of rare disease patient 
oƌgaŶisatioŶs ǁith oǀeƌ ϴϬϬ ŵeŵďeƌs, paƌt of EU‘O‘DI“͛ ŵissioŶ is to ƌepƌeseŶt ƌaƌe disease patieŶts 
and be their voice within European initiatives, projects and policy developments that affect their daily 
lives. Requests for patient perspectives in health, research and social policy-making are on the rise as 
the benefits associated with evidence-based programmes or policies, as described by Brownson 
(2009), are being increasingly recognised and required by all stakeholders. The Rare Barometer 
programme is an initiative that uses social science research methods to collate and examine the 
perspectives of patients living with a rare disease and their family, ensuring their accurate 
ƌepƌeseŶtatioŶ iŶ EU‘O‘DI“͛ adǀoĐaĐǇ ǁoƌk. The ‘aƌe Baƌoŵeteƌ pƌogƌaŵŵe hosts aŶ iŶteƌŶatioŶal 
survey panel known as Rare Barometer Voices, which was designed to address the difficulties of 
making and sustaining contact with people living with a rare disease. Members of the Rare Barometer 
Voices panel agree to regularly take part in surveys. It is also designed to ensure diverse 
representation. Diversity is achieved by recruiting through various sources, including rare disease 
organisations, social care providers, Google and Facebook adverts. Information is provided through 
online channels (i.e. Facebook, twitter, emails) and other means of communications (e.g. leaflets 
distributed during rare diseases-related events). When individuals register for Rare Barometer Voices, 
they will be asked to provide socio-demographic information such as age, gender and country of living. 
The Rare Barometer Programme aims to ĐolleĐt ƌaƌe disease patieŶts͛ peƌspeĐtiǀe oŶ a ǀaƌietǇ of topiĐs 
to provide general guidance and strategic information on relevant policies for rare disease patients 
and their families. This programme works towards identifying priorities and problems (Brownson, 
2009) within the rare disease field, and measure their magnitude and seriousness. It contributes to 
policy-agenda setting at EURORDIS and to suggest alternative or more targeted policy approaches that 
may be taken to address difficulties encountered by rare diseases patients. In 2017 for example, within 
the framework of the European Union-funded INNOVCare project (https://innovcare.eu), results of a 
survey among 3071 rare disease patients have served to assess unmet social needs of people living 
with a rare disease (EURORDIS, 2017) which then contributed to the design of an innovative care 




MATERIALS AND METHODS 
This article presents findings from a large quantitative survey conducted with patients with rare 
diseases and family members from March to May 2018. The aim of this survey was to explore patients 
and family perspectives on data sharing and data protection in research and healthcare settings. It was 
designed to be accessible to a diverse population with a wide range of education backgrounds: the 
survey was translated into 23 languages to make it accessible to non-English speakers, and was 
disseminated via patient organisations to patients who are not necessarily used to taking a position on 
a data-related policy issues, thus ensuring that a wide range of voices and experiences were 
represented.  
There were three main objectives of this quantitative study. The first was to gain a better 
understanding of the opinions, expectations and concerns about data sharing of patients with a rare 
disease and their family members. Secondly, it was hoped that the findings of this project would 
ĐoŵpleŵeŶt pƌeǀious ǁoƌk oŶ patieŶts͛ peƌspeĐtiǀes ĐoŶduĐted thƌough ‘D ĐoŶŶeĐt, eitheƌ thƌough 
confirming or refuting their main findings. Finally, it was expected that this project would lead to policy 
and research recommendations, to encourage researchers and healthcare stakeholders in charge of or 
participating in data-sharing initiatives to recognise the importance of understanding rare disease 
patient perspectives, and to encourage discussion about data sharing best practices.  
 
The target population was patients living with a rare disease or family members (parents and close 
relatives) of over 16 years old. Fieldwork started in February 2018 and ended in April 2018. Rare 
Barometer Voices participants received an email to inform them about the launch of the survey and 
inviting them to take part. Those who did not reply received 4 reminders. 1364 participants completed 
the questionnaire, yielding a response rate of 19%, which is comparable to similar studies.  
 
Information about Rare Barometer Voices containing a link to the survey was also disseminated on 
social media and through the EURORDIS network of patient organisations, and 871 responses were 
received. 2235 responses were collected in total. Questionnaires completed to more than 80% only 
were kept, duplicates and responses from respondents outside the target population were excluded 
from the analysis. 2013 responses were analysed.  
 
The questionnaire was designed in consultation with a topic expert committee representing diverse 
expertise: sociology, legal, computational biology, rare disease patient advocacy, ethics, patient 
reported outcome measurement and rare disease advocacy. It was also influenced by insights gained 
through the qualitative exercises linked to RD Connect (Thompson, 2014): focus groups exercise (Mc 
Cormack, 2016), Delphi exercise with 15 knowledgeable patients aiming at reaching consensus on 
data-sharing-related issues, group discussions with members of the Patient Advisory Council (PAC) of 
the RD Connect project. Particular questions were also influenced by previous quantitative surveys 
which have specifically focused on data sharing and data protection, including for example the 
European Commission survey programme (Special Eurobarometer, 2015, 2010), which allows 
ĐoŵpaƌisoŶ ďetǁeeŶ ƌaƌe disease patieŶts͛ peƌspeĐtiǀes aŶd those of the geŶeƌal puďliĐ.  
The questionnaire was mainly composed of close-ended questions with defined response categories, 
addressing the following areas:  
- The degree of sensitivity attributed to different types of health-related information; 
- The trust placed in different stakeholders that could be involved in data sharing initiatives;  
- The different purposes for which they would be willing to share their data; 
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- The type of information rare disease patients would need to receive to engage in a data sharing 
project; 
- The ways and the frequency to which they would want to receive information of the related projects;  
- The degree of control they would want to have over their data; and 
- The risks associated with the potential disclosure of health data. 
 
Descriptive statistics of responses are expressed in percentages. In order to improve readability and 
comprehension, most of the response categories and Likert scale items are grouped. In order to 
investigate sociodemographic factors associated with responses related to these areas, questions 
regarding sociodemographic profile and behaviour were included in the questionnaire and used as 
independent variables. These included gender, age, age at end of education, relationship to rare 
diseases (patient, carer, patient representative), use of social network, severity of the disease and 
perceived sensitivity of data. The Chi-Square test of independence was used to assess if there are 
significant differences between subgroups (McHugh, 2013). When relations between dependent and 
independent variables were not significant (based on chi squared test) and p value above 0.05, results 
were not included in the description of the results. MAPI, partner of the Rare Barometer Programme 
and expert in medical translation and Linguistic Validation, provided the translation. 
 
RESULTS 
Respondents widely support data sharing if done in the interest of rare disease patients  
Almost all respondents would be willing to make their own health data or that of the person they care 
for available for research purposes, whether it is used to develop new treatments (97%), to improve 
research on diagnosis (97%) and/or to better understand mechanisms and causes of the disease (97%). 
A vast majority of the respondents are also willing to share their data in healthcare settings, 95% being 
in favour of sharing their data to receive additional specialist advice on their care. An overwhelming 




Table 1. If given the opportunity, would you be willing to make your/the person you care for health information available for the 
purpose of: 
(n = 2013) Number of people % of responses 
Better understanding mechanisms and causes of your disease 
  
Yes* 1954 97% 
No** 40 2% 
Don’t know 19 1% 
Developing new treatments for your disease 
  
Yes* 1953 97% 
No** 41 2% 
Don’t know 19 1% 
Improving diagnosis of your disease or suspected disease 
  
Yes* 1946 97% 
No** 44 2% 
Don’t know 23 1% 
Receiving additional specialist advice on your care 
  
Yes* 1915 95% 
No** 76 4% 
Don’t know 22 1% 
Improving research and care on diseases other than yours 
  
Yes* 1803 90% 
No** 166 8% 
Don’t know 44 2% 
Carrying out research not related to the medical field 
  
Yes* 1029 51% 
No** 841 42% 
Don’t know 143 7% 
*Includes those who responded either ‘yes, definitely’ or ‘yes, probably’ 
**Includes those who responded either ‘no, probably not’ or ‘no, definitely not’ 
Because of rounding, percentage might not 
add up to exactly 100%. 
The willingness to share data for the above purposes is shared across all socio-demographic categories 
(age, gender, level of education, severity of the disease), which shows a high level of consensus on the 
idea of sharing data for care-related matters. Only respondents aged 65 and over are slightly less likely 
to share their data to improve research on diseases other than theirs (84%).  
However, only a small majority of the respondents (51%) are in favour of  sharing their data for 
purposes not related to the medical field. The socio-demographic data show that respondents over 50 
years old are less open to the idea of sharing data outside the medical field (45%) whereas the majority 
of respondents under 50 years old (55%) would be willing to share their data for this type of purpose. 
In addition, respondents with lower level of education are more open to sharing for non-medical 
purposes (59%) than those with higher levels of education (48%). Rare disease patients with more 
severe diseases are more disposed to share their data for non-medical purposes (64%) compared to 
those with less severe diseases (40%). Looking at country variations, it also appears that respondents 
from countries belonging to the European Union are less favourable (50% compared to 60% outside 
the EU) to share data for non-medical purposes. Lastly, respondents who are not active users on social 
media (who do not share information online everyday) are also less keen to share data outside the 
medical field: 43% compared to 54% among active users (who share information online everyday).  
Why participate in rare disease research? The possibility to discuss and learn about the rare disease 
are the main incentives for patients 
Respondents were asked to choose elements that would encourage them to participate in data sharing 
projects among a list of seven elements. From this list, all items related to having the possibility to 
receive more information and to learn more about their rare disease were the most quoted, about 
three times more than other items on the list. 69% think that the possibility to learn more information 
about the disease would encourage them to participate, 66% chose the possibility to discuss and ask 
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questions directly to professionals as their main incentive and 62% opted for the opportunity to be 
informed on the results of the project.  
Table 2. From the list below, what are the three main options that would encourage you to participate in a project involving the sharing of 
your/the person you care for health information? (Please select the responses in priority order) 
(n = 2013) Number of people % of responses 
The possibility to learn more information about your disease 1382 69% 
The possibility to discuss and ask questions directly to professionals involved in the 
project 1322 66% 
The possibility to be informed on the results of the project 1251 62% 
The possibility to access your health information 541 27% 
The option to withdraw the information at any point during the project 505 25% 
Being sure to be contacted if your information has been misused 478 24% 
Having the time to process the information and decide at a later stage on whether you 
want to participate 343 17% 
Other 46 2% 
I wouldn’t give the possibility of sharing these health information 28  1% 
Don’t know 25 1% 
Several answers possible, so percentage does not total 100% 
 
Sociodemographic data show that respondents residing in countries outside the European Union are 
particularly interested in learning more information about their disease: 73% think that the possibility 
to learn more information about the disease would encourage them to participate compared to 68% 
for those living in the European Union. The need for information varies across diseases from 45% of 
carers or patients affected by cystic fibrosis to 81% of patients or carers affected by systemic sclerosis 
(although the results should be considered with caution because of the variable and sometimes low 
number of respondents per disease). 
Having the possibility to discuss the disease is of particular importance for carers (69% compared to 
64% for patients) and this importance also varies across diseases, from 44% for sarcoidosis to 76% for 
myasthenia gravis.  
Following the importance of gaining more information on the rare disease; options that would give 
patients and carers the possibility to have more control over the data are selected by about one 
quarter of the respondents: 27% declare that having the possibility to access their health information 
would encourage them to participate, 25% chose the possibility to withdraw their data at any time of 
the project- this option being more important for patients with higher level of education (27%) than 
those with lower level of education (18%) - and 24% opted for the option to be contacted if their 
information has been misused. The need to be recontacted in that case is a more important element 
for respondents living in the European Union (25%) than for respondents living outside the European 
Union (17%). Lastly, the possibility to decide at a later stage if they want to participate is quoted by 
only 17%.  
Opinions are divided on the sensitivity of different types of health information 
Respondents were asked to report the level of sensitivity they associate to several types of health data. 
Respondents show mixed views about these levels of sensitivity: roughly half of them think that 
information on their disability (51/47), genetic information on their disease (49/48), physiological data 
(48/50) are sensitive (very or fairly sensitive). Symptoms (42/57) and names of the disease (33/65) are 






Table 3. Imagine you are asked to participate in a project that involves sharing your/the person you care for health information. In this 
context, how sensitive do you think each of the following types of information are? 
(n = 2013) Number of people % of responses 
Information on your disability   
Sensitive* 1022 51% 
Not sensitive** 944 47% 
Don’t know 47 2% 
Genetic information on your disease   
Sensitive* 986 49% 
Not sensitive** 961 48% 
Don’t know 66 3% 
Physiological data (e.g. blood pressure, results of biological analysis)   
Sensitive* 960 48% 
Not sensitive** 1005 50% 
Don’t know 48 2% 
Symptoms of your disease   
Sensitive* 838 42% 
Not sensitive** 1141 57% 
Don’t know 34 2% 
Name of your disease   
Sensitive* 664 33% 
Not sensitive** 1315 65% 
Don’t know 34 2% 
Because of rounding, percentage might not add up to exactly 100%. 
*Includes those who responded either ‘very sensitive’ or ‘fairly sensitive’ 
**Includes those who responded either ‘very not sensitive’ or ‘not sensitive’ 
 
The socio demographic analysis shows that older respondents (over 50 years old) tend to see all 
categories of health-related information -except information on disability- as more sensitive (53% for 
genetic information, 50% for physiological data, 44% for symptom of the disease, 35% for the name of 
the disease) than younger respondents (below 50 years old: 47% for genetic information, 46% for 
physiological data, 40% for symptom of the disease, 32% for the name of the disease). Women (52%) 
perceive information on disability as more sensitive than men (46%). The perceived sensitivity of any 
types of the above information - except information on disability - is higher among respondents who 
present themselves as patient representatives (59% for genetic information, 54% for physiological 
data, 50% for symptom of the disease, 42% for the name of the disease).  
Genetic information is of particular concern among patient representatives: 35% think that genetic 
information is very sensitive (as it appeared in the questionnaire) compared to only 27% of carers and 
23% of patients.  
Looking at the results of this question as a dependant or explanatory variable also shows that the 
willingness to share data is very lightly affected by the perceived sensitivity of data: respondents who 
perceive all type of the above health-information as sensitive are more than 90% to be willing to share 
their data for each health-related purposes.  
Respondents who think their data is sensitive require more control over their health information 
(54%). Results also demonstrate that the willingness to share and to control data are not contradictory: 
respondents who are used to share information online are also asking for control over their data (45% 
of those who use social network provide a grade of 5 – full control). This is scored even greater among 
those who never share information online (56%). 
Patients want to keep control over the data they are sharing  
Being in favour of sharing their data does not preclude respondents from wanting to keep control on 
the whole data sharing process. On a scale from 1 to 5 on which 1 represents having no control and 5 
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having the full control over their data, almost no respondent declare that they do not request any 
control over their data (1%). Respondents are overwhelmingly in favour of keeping the strictest control 
on their data: 47% choose a grade of 5 and 33% a grade of 4.  
Table 4. Still in the situation in which you/the person you care for are sharing your health information. On a scale from 1 to 5, how much 
control would you like to have over this information?  
(n = 2005) Number of people % of responses 
1 - No control (on who, how and why using your information) 21 1% 
2 77 4% 
3 301 15% 
4 671 33% 
5 - Full control (on who, how and why using your information) 935 47% 
Because of rounding, percentage might not add up to exactly 100%. 
Looking at sociodemographic data, women (48% selected give a grade of 5) are more prone to request 
control over their data than men (42%). Respondents residing in the European Union are also in favour 
of more control (48% selected grade 5) than respondents coming from countries outside the European 
Union (37%). 
 
The uses of data under unchosen circumstances are the mains risks associated with sharing data 
In line with the importance attached to controlling their data, rare disease patients are concerned that 
their data could be used by third parties with which they would not have chosen to share their data 
(50%). For most this is the most prominent risk they associate with the disclosure of their personal 
data. They are almost equally concerned that their data could be used in a context they would not 
have chosen (47%). The third risk would be to see their information being used without being aware 
of it (35%).  
More than one third of the respondents are apprehensive of becoming victims of discrimination (34%) 
as well as their identity being used for fraudulent purposes (32%). Uses that could produce direct and 
harmful consequences such as becoming victim of a fraud (20%) or their personal safety being at risk 
(12%) are less seen as potential risks for rare disease patients than the previous ones.  
Table 5. Below is a list of potential risks. According to you, what are the most important risks connected with disclosure of your personal 
or health information? (Please select three responses in priority order) 
(n = 2013) Number of people % of responses 
Your information being shared with third parties (companies or government agencies) 
without your consent 978 50% 
Your information being used in different context from the ones where you disclosed it 915 47% 
Your information being used without your knowledge 683 35% 
Becoming the victim of discrimination (e.g. in job recruitment, being charged higher 
prices, not being able to access a service) 662 34% 
Your online identity being used for fraudulent purposes 620 32% 
Your information being used to send you unwanted commercial offers 407 21% 
Becoming a victim of fraud 392 20% 
Your personal information being stolen 348 18% 
Your personal safety being at risk 314 16% 
Your views and behaviours being misunderstood 177 9% 
Your reputation being damaged 100 5% 
Your personal information being lost 89 5% 
I wouldn’t give the possibility to share my health data 28 1% 
None 19 1% 
Other 11 1% 
Several answers possible, so percentage does not total 100%   
Rare disease patients show higher level of confidence in not-for-profit stakeholders 
Respondents were asked whether they trust various authorities and type of organisations to handle 
and use their health information carefully. Trust in not-for-profit stakeholders (89% for medical 
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doctors, 79% researchers from non-profit organisations, 77% for patient organisations, 69% for 
healthcare professionals other than medical doctors) is considerably higher than trust in for profit 
stakeholders. Among stakeholders from the not-for-profit sector, medical doctors involved in the 
ƌespoŶdeŶts͛ healthĐaƌe aƌe the ŵost tƌusted ;alŵost ϵ iŶ ϭϬ ƌespoŶdeŶtsͿ. “iŵilaƌlǇ, confidence in 
patient organisations is very high (77%). Patients representatives show a high level of confidence (83%) 
toward this type of organisation, but so do patients (83%) and carers who do not identify themselves 
as representative (76%). Opinions on governments and institutions from the respondents͛ ĐouŶtƌǇ aƌe 
more divided (48% show confidence compared to 47% who show little confidence), but more 
confidence is stated towards governments and institutions from the European Union (51%) than from 
other countries (31% compared to 61%). Cross-analysis shows that patient representatives tend to 
trust their government (60% confident compared to 38%) more than patients (47% confident 
compared to 49% not confident) or carers (54% confident compared to 43% not confident) who are 
not engaged in advocacy activities. Sociodemographic tables also show that more educated 
respondents (those who finished education when they were 20 or more) tend to trust government and 
institution from their country more (53%) than those who finished school earlier (44% among those 
who finished school before 20 years old).  
Table 6. Imagine you are still in a situation in which you are asked to participate in a project that involves sharing your/the person you care 
for health information. People involved in the project can belong to different types of organisations. How much confidence do you have in 
each of them to handle and use your health information carefully? 
 (n = 2013) No of people % of responses 
Medical doctor involved in your healthcare Confidence* 1795 89% 
Little confidence** 198 10% 
Don’t know 20 1% 
Researcher from a non-profit organisation (e.g. university or 
public hospital) 
Confidence* 1592 79% 
Little confidence** 360 18% 
Don’t know 61 3% 
Patient organisation Confidence* 1546 77% 
Little confidence** 391 19% 
Don’t know 76 4% 
Healthcare professionals other than medical doctors (e.g. dentists, 
pharmacists, nurses, physiotherapists) 
Confidence* 1381 69% 
Little confidence** 571 28% 
Don’t know 61 3% 
Government or institution from a country within the European 
Union 
Confidence* 1017 51% 
Little confidence** 860 43% 
Don’t know 136 7% 
Government or institution from your country Confidence* 988 48% 
Little confidence** 946 47% 
Don’t know 79 4% 
Researcher from a private genetic testing company Confidence* 956 47% 
Little confidence** 936 46% 
Don’t know 121 6% 
Researcher from a pharmaceutical or medical device company Confidence* 911 45% 
Little confidence** 1010 50% 
Don’t know 92 5% 
Government or institution from a country outside Europe Confidence* 625 31% 
Little confidence** 1219 61% 
Don’t know 169 8% 
An insurance company Confidence* 315 16% 
Little confidence** 1619 80% 
Don’t know 79 4% 
Because of rounding, percentage might not add up to exactly 100%. 
*Includes those who responded either ‘a great deal’ or ‘quite a lot’  
**Includes those who responded either ‘not very much’ or ‘none at all’ 
Regarding the private sector, opinions are divided about researchers working for the pharmaceutical 
industry (45% are in favour and 50% are opposed). However, a large majority of the respondents are 
opposed to sharing their data with insurance companies (16% are in favour and 80% are opposed). 
Sociodemographic analysis shows that the older respondents are less likely to trust the private sector: 
57% of respondents under 25 trust researchers from pharmaceutical industry compared to 36% for 
respondents over 65 and only 28% compared to 9% for insurance companies.   
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Opinions are fragmented on whether responsibility could be delegated to an ethics committee 
A relative majority (49%) would allow an ethics committee to decide on their behalf with whom their 
information could be shared, 43% are against the idea and 8% do not have an opinion. The 
sociodemographic data shows that men (58%) are more disposed to let an ethics committee decide 
for them than women (46%). Willingness to delegate responsibility to an ethics committee 
corresponds with increasing age. Respondents over the age 50 were more ready to delegate decisions 
(52% among respondents aged 50 to 64 and 59% among 65 and older) compared to younger 
respondents who are willing to delegate (40% under 24, 42% between 25 and 34 and 48% between 35 
and 49). People residing outside the European Union are more willing to delegate to an ethics 
committee (67%) than those living in the European Union (46%).  
 
Table 7. Would you allow an ethics committee to decide on your behalf with whom your information will be shared, how and why? 
(n = 2005) Number of people % of responses 
Yes* 980 49% 
No** 863 43% 
Don’t know 162 8% 
Because of rounding, percentage might not add up to exactly 100%. 
*Includes those who responded either ‘yes, definitely’ or ‘yes, probably’ 
**Includes those who responded either ‘no, probably not’ or ‘no, definitely not’ 
Communicating with patients 
When asked directly if they would like to be informed about the outcome of a data-sharing project in 
which they are participating, almost 100% of the respondents (99.7%) answer positively. This 
percentage is higher than the one presented earlier in the results chapter because is it not presented 
to respondents in competition with other items (62% opted for the opportunity to be informed on the 
results of the project, see table 2).  
Knowing about the outcome and understanding the main features of the project are the most 
important information for patients to receive 
Receiving details on how the project could be beneficial to their disease or other diseases is the most 
important piece of information for the respondents (80% of the sample selecting this option, compared 
to much lower percentages selecting the rest of the possibilities). Around half of the respondents want 
to receive an easily understandable summary of project (51%) and information about the management 
rules (49%). Around 40% want to know about the professionals involved in the project and how these 
professionals might benefit from the project. Information on measures taken to prevent security 
breaches are selected by less than one third of the respondents (28%).  
Table 8. From the list below, what are the three main pieces of information about the project that would be important for you to receive? 
(Please select three responses in priority order) 
(n = 2013) Number of people % of responses 
Detail on how the project could be beneficial for your disease or other diseases 1605 80% 
Brief summary of the key information necessary to understand the main aspects of the 
project 1032 51% 
Information about the data management rules (ie. how access to my health information 
will be granted or is there an ethical review ?) 988 49% 
Information about professionals involved in the project who can access the health 
information (e.g. their biography) 797 40% 
Information on how professionals involved in the project might benefit professionally 
from accessing my health information 750 37% 
Information on the measures taken to prevent security breaches 561 28% 
Don’t know 64 3% 
I wouldn’t give the possibility of sharing these health information 28 1% 
Other 26  1% 
Several answers possible, so percentage does not total 100% 
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The hierarchy of importance does not vary significantly across socio-demographic categories. 
Respondents favour most common way of receiving information such as emails or face to face 
discussion  
About 9 in 10 of the respondents would like to be informed by emails or during face-to-face 
discussions, these opinions are equally shared across socio-demographic categories. 85% would like to 
receive information through a dedicated website, but this option is favoured by respondents who are 
active users on social media (89%) compared to those who are not social media users (77%). Almost 7 
in 10 would be prepared to attend a conference to learn about the project in which their data is 
involved, which is less than other items but still represents a large majority of the respondents. 
Opinions on receiving information through a mobile app are more divided. Respondents below the age 
of 50 (59% under 24, 70% between 25 and 34) are much more open to consulting a mobile app than 
respondents over 50 (49% among 50-64, 37% among 65 years old and older). Respondents coming 
from countries outside the EU are also more disposed to receiving information through a mobile app 
(62%) compared to EU residents (55%).  
Table 9. Would you like to be informed about the outcome of the project through each of the following means? 
(n = 2005) Number of people % of responses 
Emails   
Yes* 1863 93% 
No** 127 6% 
Don’t know 15 1% 
Face to face discussion with professionals involved in the project   
Yes* 1718 86% 
No** 235 12% 
Don’t know 52 3% 
A dedicated website   
Yes* 1706 85% 
No** 250 12% 
Don’t know 49 2% 
Attending conferences   
Yes* 1349 67% 
No** 558 28% 
Don’t know 98 5% 
A mobile app   
Yes* 1119 56% 
No** 819 41% 
Don’t know 67 3% 
Because of rounding, percentage might not add up to exactly 100%. 
*Includes those who responded either ‘yes, definitely’ or ‘yes, probably’ 
**Includes those who responded either ‘no, probably not’ or ‘no, definitely not’ 
 
The ideal frequency to be informed for a majority of the respondents is once a month (55%). It can also 
be noted that some respondents would favour more frequents updates (21%), in particular 
respondents under 35 years old (31% among under 24 and 27% among 25-34 years old) and 
respondents coming from outside the European Union (31%). 
Table 10. And how often would you like to be informed about the outcome of the project? 
(n = 2005) Number of people % of responses 
Several time a week 112 6% 
Once a week 427 21% 
Once a month 1 101 55% 
Once a year 241 12% 
Don’t know 124 6% 
 
DISCUSSION  
The results of this large quantitative survey strongly substantiate previous findings among a wider rare 
disease patient population. Rare disease patients and representatives, regardless of the severity of 
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their disease and their socio-demographic profile, are clearly willing to share their data to foster 
research and improve healthcare. Results also show that the perceived sensitivity of data does not 
prevent rare disease patients to be willing to share them. This aligns with qualitative work focusing on 
the perspectives of rare disease patients on data sharing which showed that patients are positively 
disposed towards participating in research and allowing their own data or data from family members 
they care for to be shared internationally. Compared to the general population, rare disease patients 
seem to be more inclined to share their data. In a study carried out by YouGov in 2018 in several 
European countries and among the general population, only 37% of the respondents declare that they 
would be ready to share their data to develop medicine and treatments. The support for data sharing 
in the context of rare disease research is aligned with the work undertaken by the European Reference 
Networks to establish a dedicated data-sharing platform enabling information exchange and mutual 
leaƌŶiŶg to iŵpƌoǀe ƌaƌe disease patieŶts͛ diagŶosis and care, while also contributing to the 
development of research and innovation. A politically significant initiative was launched last year, with 
the signature by several EU countries of a declaration whereby their governments commit to 
cooperate to deliver cross-border access to genomic information. This declaration has the potential to 
maximise use of health care resources and advance the development of personalised medicine 
especially in the rare disease field (EU countries will cooperate in linking genomic databases across 
borders, 2017).  
Recently, the European Commission released a recommendation to securely share electronic health 
records across Europe, building on existing programs to share e-prescriptions and patient summaries. 
The Commission wants to create a framework for an EU-wide exchange platform where national 
systems would be able to exchange information. The potential impact of this recommendation will be 
entirely dependent on the willingness of countries to make the necessary investments in their national 
health IT infrastructure (European Commission, 2019).  
Electronic health records do not yet exist in most EU countries for a number of reasons including lack 
of interoperability, fragmentation, the large amount of unstructured data and also to some extent a 
lack of trust in private companies to provide this kind of service. However, there is a trend in Europe 
showing an emerging political support from several countries to invest in health data hub and 
electronic health records (French minister for health announce creation of a data hub, 2018). Sharing 
of health data through the implementation of electronic health records across Europe will enable 
optimised use of health data to improve healthcare and outcomes for patients as well as promoting 
research. Furthermore, rare disease patients have expressed their willingness to share their own data 
for the benefit of others. Indeed, rare disease patients acknowledge the fact that the project in which 
they are participating will not necessarily have an impact on their quality of life but rather on that of 
future or younger patients affected. Helping patients affected by their disease in the future or patients 
affected by other diseases has proven to be the strongest incentive for patients to participate in 
research initiatives (CISRP 2017, EURORDIS 2018). The fact that patients are motivated to enrol in 
clinical studies they believe to be scientifically or socially important has been demonstrated among 
wider patient populations (Odierna, 2014).  
 
However, rare disease patieŶts͛ ǁilliŶgŶess to shaƌe theiƌ data does Đoŵe ǁith speĐific conditions and 
requirements. For most patients, it is important to: 
 Control how and for which purpose their health data will be shared 
Being in favour of sharing data and calling for more control are not contradictory, they are clearly 
stated as two parallel requirements. Respondents clearly need to be at the centre of data-driven 
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innovation and to be recognised as active agent in data sharing initiatives in which they participate. 
The current regulatory environment coupled with the trend in public debate sparkled by news on 
various data breaches, including on social media, are factors contributing to the need for greater 
control especially by respondents living in the European Union. According to the General Data 
protection Regulation (Article 6(4); Recital 502018), organisations that process personal data for 
research purposes may avoid restrictions on secondary processing and on processing sensitive 
Đategoƌies of data iŶĐludiŶg health data. Hoǁeǀeƌ, patieŶts͛ ƌeƋuest foƌ ĐoŶtƌol oǀeƌ theiƌ data ďuild 
the case to enable patients to express preferences regarding the use of their data.  
Results also show that views regarding the sensitivity of data, preferences in terms of frequency and 
means to be informed and trust in stakeholders vary significantly by sociodemographic profile. Echoing 
these trends, dynamic systems have started to emerge as tools that would enable to provide regular 
and accessible information to patients regarding the purpose and outcome of the projects whilst 
allowing patients to select and tailor their preferences related to when, how and who can use their 
data, thus respecting individual preferences with the possibility to amend these over time (Spencer et 
al. 2016). More specifically, the concept of dynamic consent has been recently tested and reviewed 
(Budin-Ljøsne et al., 2017) offering the additional potential for improving research outcomes and 
providing the adapted and flexible system that will be much needed in view of the future technological 
and regulatory/legal changes in the European health systems. Person-centred approaches and digital 
solutions are also pushed forward in the Communication on the transformation of Health and Care in 
the Digital Single Market to organising health and care to allow citizens to actively engage in their 
health and access scientific information more easily.  
 Minimise risks and respect concerns whilst promoting research 
The perceived specific sensitive nature of genetic and genomic data and the additional vigilance to the 
way this data should be handled compared to other health data has been reported in previous 
qualitative studies (McCormack et al, 2016, RD-Connect Delphi exercise). This view is more nuanced 
among the present sample of respondents as information on disability is seen as the most sensitive 
aŵoŶg the list ;ϱϭ% Đoŵpaƌed to ϰϵ%Ϳ. Fuƌtheƌŵoƌe, iŶ theiƌ ƌepoƌt ͞GeŶoŵe seƋueŶĐiŶg: ǁhat do 
patieŶts thiŶk͟ puďlished iŶ ϮϬϭϱ, GeŶetiĐ AlliaŶĐe UK states that ϵϯ% of the surveyed patients do 
welcome the sharing of their genomic data for research purposes. The Genetic Alliance UK report adds 
that patients consider a lack of genomic data sharing as an hindrance to scientific research progress 
which in turn would be counter-intuitive to their hope for a better quality of lives.  
The perceived sensitivity of information on disability can be linked to discrimination rare disease 
patients are experiencing with regard to their condition on a daily basis, in particular in a school or 
work environment, which was widely reported in previous qualitative activities (McCormack et al., 
2016) and other Rare Barometer surveys (EURORDIS, 2017). Ethical and responsible data sharing 
should be enabled through widespread implementation of the IRDiRC recognised resource, the 
international charter of principles for sharing bio-specimens and data which provides guidance for 
effective legally- and ethically-grounded data sharing. Furthermore, several ongoing initiatives are 
testing the use of the blockchain technology to protect personal data (Zyskind et al., 2015). 
Biotechnology companies are also using blockchain to share and protect genomic data (e.g. 
Genomes.io).  
 
 Increase transparency and improve communication  
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Ensuring patient trust and confidence in the different projects involving data sharing will help 
sustainable patient participation and increase the chance of successful outcomes for the project. In 
healthcare settings, it is also associated with better health outcomes in improving treatment 
adherence, for instance. The results clearly demonstrate that rare disease patients show various levels 
of trust in different actors and stakeholders who could be involved in data sharing platforms and 
initiatives. Trust in public bodies who are most of the time initiating and supervising data-sharing 
initiatives hardly reaches half of the respondents. This has to be considered in a context in which trust 
toward governments in general and among the general public (OECD Government at a glance report 
2017) is low and decreasing. On average in OECD countries, in 2017, only 42% of citizens report having 
confidence in their government compared 47% in 2007. Lessons should be learned from the collapse 
of NH“ EŶglaŶd͛s Đaƌe data programme which was paused in 2014 and later abandoned largely due to 
a loss of public trust (Spencer et al, 2016). Also, the high level of trust towards healthcare professionals 
involved in rare disease patieŶt͛s dailǇ Đaƌe is important: data sharing initiatives would certainly benefit 
from involving general practitioners and other healthcare professionals in the management and 
communication of data sharing initiatives. Interestingly, the Caldicott report states that specific 
measures need to be taken to gain public trust including better technology standards, proper 
marketing of the benefits, an easy opt-out pƌoĐeduƌe, aŶd a ͞dǇŶaŵiĐ ĐoŶseŶt͟ pƌoĐess (Mathers et 
al; 2017). Similarly, respondents expressed different levels of confidence on the ability of ethics 
committees to grant access to users of their data. Therefore, governance of data sharing initiatives and 
platforms should include a variety of actors to instigate confidence in the initiatives and ensure patient 
participation.  
The good practices developed and implemented within the framework of the FP7-funded project RD-
Connect for the governance of the platform provide confidence to patients and also researchers who 
deposit data in the platform. The project partners have developed a Code of Conduct to which users 
of the RD-Connect platform must adhere to in order to gain access. An additional safeguard is ensured 
by the data access committee who review all requests for access for the platform and to rule on 
ĐiƌĐuŵstaŶĐes ǁheƌe a useƌ͛s access may be revoked for lack of adherence to the Code of Conduct or 
other breach of best practice. This committee includes bioinformaticians, clinicians, researchers and 
patient representatives.  
The survey has emphasised the need for rare disease patients to gain access to information related to 
their disease. It is important to enable rare disease patients to better understand their own health with 
easier access to information. The rarer the disease, the greater the need for patients - already experts 
on their disease - to continue to build knowledge on every aspect of their disease and enable them to 
share updated information with their peers. Scientists, clinicians, patients, industry and policy makers 
concerned with progress in rare disease research, healthcare and policy, ultimately share a similar goal, 
which is to ensure faster access to accurate diagnosis and improve healthcare. Therefore, impactful 
communication within the community needs to be made of strong and accessible common messages 





The findings of this project add to the emerging literature about patient engagement in rare disease 
research and the value of, and barriers to, sharing data. The work of EURORDIS on this present survey 
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oŶ patieŶts͛ peƌspeĐtiǀe aŶd suggested ƌeĐoŵŵeŶdatioŶs ĐaŶ iŶfoƌŵ the ŵoǀiŶg laŶdsĐape of data 
sharing and contribute to this paradigm shift of new norms and expectations. 
Taking into account, i) the results of this survey, ii) previous qualitative studies and rare disease 
patients discussion groups, iii) the evidence-based policy work of EURORDIS, seven recommendations 
are detailed below. The goal of these recommendations is to inform and support stakeholders involved 
in data sharing to shape all relevant initiatives.  
 
Recommendation 1: Policy makers should ensure implementation of appropriate legislations 
at European and national levels and pursue efforts to foster cultural, technological and 
infrastructural changes to further develop international data sharing initiatives in health and 
research for rare diseases.  
Recommendations 2 and 3: Governing structures of data-sharing initiatives should:  
 Develop and implement robust standards to ensure secure, ethical and 
responsible data sharing whilst putting in place safeguards around data 
protection;  Include representatives from trusted advocacy organisations, i.e. patient 
organisations and non-profit organisations as well as clinicians and healthcare 
professionals.  
 
Recommendation 4:  All stakeholders involved in data sharing initiatives need to promote the 
development of, and implement,  dynamic systems enabling: i) the possibility to express 
different attitudes and preferences and ii) access to updated information on research 
outcomes to increase patient participation in research and stimulate data sharing whilst 
ƌespeĐtiŶg patieŶts͛ pƌefeƌeŶĐes. 
Recommendation 5: All stakeholders involved in data sharing initiatives including healthcare 
systems and  other relevant authorities should allocate resources at national and regional 
levels to enable the development of, and facilitate access to, relevant educational resources 
to enable informed choices for patients to share or not to share their health-related data.  
Recommendation 6: fundersFunders and sponsors of data sharing activities should ensure 
that adequate financial resources are allocated to improve communication and increase 
transparency on the purpose and outcomes of data sharing initiatives to maximise the benefits 
of the project outcomes.  
Recommendation 7: Funders, clinicians and researchers need to emphasise potential health 
benefits of research studies and healthcare initiatives on future generations and other disease 




Although this is a significant, large scale survey there are several limitations that future researchers 
might need to take into account. Participants were identified through a large database of patients who 
have previously identified themselves as willing to take part in research and surveys to support the 
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work of EURODIS, which might suggest a particular perspective about the value of research and patient 
participation. Patients with rare disease who are not on the Rare Barometer Voices database are a 
much harder to reach population. It is also important to note the over representation of female 
respondents in this sample, which highlights that men with rare disease or male family members are 
an important, yet under researched population. Although we recognise that these results might not 
be generalizable to all patients and all rare disease groups, this study represents an important step in 
understanding the views of those with rare disease and has led to recommendations to support future 
research and patient engagement. 
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Additional file 1: Profile of the respondents 
 Number of people % of responses 
Age (n = 2013) 
  
15-17 2 0% 
18-24 70 3% 
25-34 293 15% 
35-49 852 42% 
50-64 644 32% 
65 or older 152 8% 
Gender (n = 2013) 
  
Female 1534 76% 
Male 473 23% 
Other 6 0% 
Country of residence (n = 2013)   
European Union 1775 88% 
Outside the European Union 238 12% 
Diagnostic status (n = 2013)   
Diagnosed 1909 95% 
Undiagnosed 104 5% 
Number of rare diseases (n = 1909)   
1 1664 87% 
2 174 9% 
3 44 2% 
4 13 1% 
5 or more 14 1% 
 
In terms of repartition of the population, proportions are quite similar to the general population. A 
large part of the sample is living in the European Union. Female proportion is high (76/24) compared 
to the general population (52/48). This figure reflects the fact that the primary carer role for people 
living with rare diseases is primarily assumed by the mother (EURORDIS, 2017, 71% of parents living 
with a rare disease identify the mother as the main carer in the household). More than 90% of the 
sample is diagnosed and 5% are not diagnosed. These lateƌ ĐaŶ ďe eitheƌ ͚Not Ǉet diagŶosed͛ ŵeaŶiŶg 
that their disease has not been diagnosed because they have not been referred to the appropriate 
clinician due to misleading symptoms, or an unusual clinical presentation of a known rare condition or 
͚UŶdiagŶosed͛ ŵeaŶiŶg that theǇ aƌe affeĐted ďǇ a disease foƌ ǁhiĐh a diagŶostiĐ test is not yet 
available (EURORDIS, 2016).  
Additional file 2: Relationship with rare diseases 
Are you a … (several answers possible) 
(n = 2321) Number of people % of responses 
Parent of a child or adult with a rare disease 642 32% 
Sibling of a child or adult with a rare disease 50 3% 
Other family member 86 4% 
Patient 1360 68% 
Patient representative 167 8% 
Other 16 1% 




The majority of the sample (68%) is composed of patients living with a rare disease and 32% of parents 
with a child or adult living with a rare disease. Among the total sample, 8% of the respondents are 
patient representatives, meaning that they are involved in advocacy activities related to rare diseases.  
Additional file 3: Repartition by group of diseases   
In order to collect information on the disease, the Orphanet (the online reference portal for 
information on rare diseases and orphan drugs) inventory of diseases was used. If participants were 
diagnosed, they were able to select their condition from 14 318 modalities (or diseases). Diseases are 
grouped in of the 24 grouping of diseases for the European Reference Networks (see EURORDIS 
Proposal for grouping of diseases for ERNs in Evangelista et al., 2016). Among respondents, 1909 
people were diagnosed and 1820 specified their disease. 1780 were then classified. The repartition 
into groupings is as follow:   
 Number of people % of responses 
Group of diseases represented in the sample  
Multiple answer (n = 1780)   
Rare Neurological Diseases 222 12% 
Rare Malformations, Developmental Anomalies & Rare Intellectual 
Disabilities 195 11% 
Rare and Undiagnosed Skin Disorders 181 10% 
Rare Connective Tissue & Musculoskeletal 156 9% 
Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases 162 9% 
Rare Pulmonary Diseases 142 8% 
Rare Neuromuscular Diseases 149 8% 
Rare Hereditary Metabolic Disorders 126 7% 
Rare Bone Diseases 106 6% 
Rare Endocrine Diseases 92 5% 
Rare Haematological Diseases 62 3% 
Rare Hepatic Diseases 55 3% 
Genetic Tumour Risk Syndromes 45 2% 
Rare Multisystemic Vascular Diseases 39 2% 
Rare and Complex Epilepsies 35 2% 
Adult Solid Rare Cancer 38 2% 
Rare Eye Diseases 33 2% 
Rare Renal Diseases 18 1% 
Rare Gastrointestinal Diseases 24 1% 
Rare & Complex Urogenital Diseases and Conditions 13 1% 
Rare Craniofacial and ENT Disorders 9 1% 
Rare Cardiac 8 0% 
Paediatric cancer 1 0% 
Total 1911 107% 
 
Additional file 4: Diseases with more than 20 respondents 
 
(n =1820) Number of people % of responses 
Other diseases 1461 80% 
Ehlers-Danlos syndrome 73 4% 
Sarcoidosis 52 3% 
Osteogenesis imperfecta 42 2% 
Meunière disease 36 2% 
Lupus erythematosus 31 2% 
Systemic sclerosis 31 2% 
Myasthenia gravis 25 1% 
Williams syndrome 25 1% 
Neurofibromatosis type 1 24 1% 
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Cystic Fibrosis 20 1% 
Because of rounding, percentage might not add up to exactly 100 
 
 
Additional file 5: Repartition by country 
 
Which country do you live in? 
(n = 1997) Number of people % of responses 
France 240 12% 
Spain 238 12% 
Germany 195 10% 
Italy 170 8% 
United Kingdom 145 7% 
Netherlands 96 5% 
Finland 82 4% 
Croatia 71 4% 
Belgium 70 3% 
Romania 66 3% 
Denmark 60 3% 
Portugal 58 3% 
United States of America 44 2% 
Czech Republic 41 2% 
Switzerland 38 2% 
Sweden 32 2% 
Hungary 30 1% 
Russia 30 1% 
Greece 29 1% 
Poland 27 1% 
Austria 26 1% 
Norway 20 1% 
Luxembourg 19 1% 
Ireland 15 1% 
Ukraine 14 1% 
Cyprus 13 1% 
Malta 13 1% 
Australia 12 1% 
Bulgaria 11 1% 
Mexico 11 1% 
Slovakia 11 1% 
Canada 8 0% 
Lithuania 8 0% 
Serbia 8 0% 
South Africa 7 0% 
Slovenia 5 0% 
Chile 4 0% 
India  4 0% 
Latvia 4 0% 
Malaysia 4 0% 
Bosnia and Herzegovenia 3 0% 
Argentina 2 0% 
Belarus 2 0% 
Brazil 2 0% 
Ecuador 2 0% 
Macedonia 2 0% 
Saudi Arabia 2 0% 
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Algeria 1 0% 
Andorra 1 0% 
Central African Republic 1 0% 
Because of rounding, percentage might not add up to exactly 100%. 
 
